Chorea associated with high titers of antiphospholipid antibodies in the absence of antiphospholipid antibody syndrome.

Safarpour D, Buckingham S, Jabbari B.

Tremor Other Hyperkinet Mov (N Y). 2015 Feb 13;5:294. doi: 10.7916/D8DB80M9.

Neurodegenerative disease: Restoring balance in Huntington disease.

Whalley K.

Nat Rev Neurosci. 2015 Feb;16(2):66-7. doi: 10.1038/nrn3906. No abstract available.

Out of one mutation, many Huntington's disease effects.

Albin RL.

Lancet Neurol. 2015 Nov;14(11):1071-2. doi: 10.1016/S1474-4422(15)00247-1. No abstract available.

Post-infectious autoimmune disorders: Sydenham's chorea, PANDAS and beyond.

Williams KA, Swedo SE.

Brain Res. 2015 Aug 18;1617:144-54. doi: 10.1016/j.brainres.2014.09.071. Review.

Clinical and Molecular Features of Late Onset Huntington Disease in a Peruvian Cohort.

Cornejo-Olivas MR, Inca-Martinez MA, Espinoza-Huertas K, Veliz-Otani D, Velit-Salazar MR, Marca V, Ortega O, Cornejo-Herrera IF, Lindo-Samanamud S, Mora-Alferez P, Mazzetti P.

J Huntingtons Dis. 2015;4(1):99-105.

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study.

Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, Roos RA, Leavitt BR, Papoutsi M, Landwehrmeyer GB, Reilmann R, Borowsky B, Johnson H, Mills JA, Owen G, Stout J, Scahill RI, Long JD, Rees

EBioMedicine. 2015 Aug 4;2(10):1420-9. doi: 10.1016/j.ebiom.2015.08.002.

Theory of mind can be impaired prior to motor onset in Huntington's disease.

Eddy CM, Rickards HE.

Neuropsychology. 2015 Sep;29(5):792-8. doi: 10.1037/neu0000190.

Exercise testing and training in people with Huntington's disease.

Dawes H, Collett J, Debono K, Quinn L, Jones K, Kelson MJ, Simpson SA, Playle R, Backx K, Wasley D, Nemeth AH, Rosser A, Izardi H, Busse M.

Clin Rehabil. 2015 Feb;29(2):196-206. doi: 10.1177/0269215514540921.

Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.

Wityak J, McGee KF, Conlon MP, Song RH, Duffy BC, Clayton B, Lynch M, Wang G, Freeman E, Haber J, Kitchen DB, Manning DD, Ismail J, Khmelnitsky Y, Michels P, Webster J, Irigoyen M, Luche M, Hultman M,

J Med Chem. 2015 Apr 9;58(7):2967-87. doi: 10.1021/jm5013598.

Altered sensory experience exacerbates stable dendritic spine and synapse loss in a mouse model of Huntington's disease.

Murmu RP, Li W, Szepesi Z, Li JY.

J Neurosci. 2015 Jan 7;35(1):287-98. doi: 10.1523/JNEUROSCI.0244-14.2015.

Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.

Ragot A, Pietropaolo S, Vincent J, Delage P, Zhang H, Allinquant B, Leinekugel X, Fischer A, Cho YH.

Brain Behav. 2015 Sep;5(9):e00361. doi: 10.1002/brb3.361.

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O.

Neurotherapeutics. 2015 Jan;12(1):185-99. doi: 10.1007/s13311-014-0304-z.

Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.

Krause A, Mitchell C, Essop F, Tager S, Temlett J, Stevanin G, Ross C, Rudnicki D, Margolis R.

Am J Med Genet B Neuropsychiatr Genet. 2015 Oct;168(7):573-85. doi: 10.1002/ajmg.b.32332.

Case report: concurrent Wilson disease and Huntington disease: lightning can strike twice.

Zanko A, Abrams L.

J Genet Couns. 2015 Feb;24(1):40-5. doi: 10.1007/s10897-014-9789-1. No abstract available.

Donor-Specific Anti-HLA Antibodies in Huntington's Disease Recipients of Human Fetal Striatal Grafts.

Porfirio B, Paganini M, Mazzanti B, Bagnoli S, Bucciantini S, Ghelli E, Nacmias B, Putignano AL, Rombolà G, Saccardi R, Lombardini L, Di Lorenzo N, Vannelli GB, Gallina P.

Cell Transplant. 2015;24(5):811-7. doi: 10.3727/096368913X676222.